AbbVie ABBV Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $4.23B-1.8% | $4.31B-11.6% | $4.87B-58.9% | $11.85B+2.6% | ||
| $955M+4.8% | $911M+22.0% | $747M+11.3% | $671M-3.0% | ||
| —— | -$1.45B+49.8% | -$2.89B-49.6% | -$1.93B-115% | ||
| —— | —— | -$66M— | —— | ||
| $236M-26.0% | $319M— | —— | $686M— | ||
| —— | $177M-95.4% | $3.84B+117% | $1.77B+2.9% | ||
| $19.03B+1.2% | $18.81B-17.7% | $22.84B-8.4% | $24.94B+9.5% | ||
| $1.21B+24.6% | $974M+25.4% | $777M+11.8% | $695M-11.7% | ||
| —— | —— | $0-100% | $255M— | ||
| -$6.64B+68.1% | -$20.82B-936% | -$2.01B— | —— | ||
| $11.66B+5.7% | $11.03B+4.6% | $10.54B+4.9% | $10.04B+8.4% | ||
| $980M-42.6% | $1.71B-13.4% | $1.97B+32.6% | $1.49B+59.2% | ||
| —— | —— | $0— | —— | ||
| -$12.72B— | —— | -$17.22B+30.6% | -$24.8B-30.3% | ||
| —— | —— | $5M— | —— | ||
| -$295M+96.0% | -$7.29B— | —— | —— | ||
| $3B+6.8% | $2.81B+13.9% | $2.47B-3.0% | $2.55B-6.1% | ||
| —— | $508M— | —— | —— | ||
| $3M— | —— | $225M+49.0% | $151M-29.1% | ||
| $2.87B+43.6% | $2B+129% | $870M— | —— | ||
| $7.44B-1.9% | $7.59B-4.4% | $7.94B+4.2% | $7.62B-1.3% | ||
| $6.5B+72.2% | $3.77B-26.5% | $5.13B+72.4% | $2.98B+11.0% | ||
| $762M-0.3% | $764M+1.6% | $752M-3.3% | $778M-3.1% | ||
| —— | -$3.26B— | —— | $542M+142% | ||
| —— | —— | $188M-28.8% | $264M— | ||
| $3M— | —— | $225M+49.0% | $151M-29.1% | ||
| $29M+115% | -$189M— | —— | -$774M-111% | ||
| $5.24B+73.2% | $3.02B+147% | $1.22B+127% | $539M-60.9% | ||
| $2.8B— | —— | $0— | $0— | ||
| —— | $57M— | —— | —— | ||
| —— | $0— | $0— | —— | ||
| $6.8B-29.3% | $9.61B+132% | $4.15B-71.3% | $14.43B+53.3% | ||
| —— | —— | —— | —— | ||
| $17.82B-0.1% | $17.83B-19.2% | $22.06B-9.0% | $24.25B+10.3% | ||
| $17.82B-0.1% | $17.83B-19.2% | $22.06B-9.0% | $24.25B+10.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does AbbVie generate?
- AbbVie (ABBV) generated $21.2B in operating cash flow over the trailing twelve months.
- What is AbbVie's free cash flow?
- After $1.2B of capital expenditures, AbbVie's free cash flow was $20.0B over the trailing twelve months, up 29.9% year over year.
- Where does AbbVie's cash flow data come from?
- Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
